Mercaptopurine NDC 51407-983

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-983Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0983Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-983-25	51407098325	250 TABLET in 1 BOTTLE, PLASTIC (51407-983-25)Marketed from Jan 19, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mercaptopurine
Generic name (nonproprietary): mercaptopurine
Active ingredients: Mercaptopurine — 50 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040528
Marketing start: Feb 13, 2004
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 51407-983_4bae6ff1-db75-6704-e063-6294a90a7f0bSPL ID 4bae6ff1-db75-6704-e063-6294a90a7f0bSPL set ID 4bae5ffb-a535-3fa0-e063-6294a90aa90aRxCUI 197931UNII E7WED276I5
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407098325 followed by a unit qualifier and the quantity

Package 51407-0983-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 25, 2026.

Indications (excerpt from the label)

Mercaptopurine Tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. (1.1) 1.1 Acute Lymphoblastic Leukemia Mercaptopurine Tablets are indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040528

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040528
Product	Strength	Form · route	Labeler	Product NDC
Mercaptopurine	Mercaptopurine 50 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-4581